drugset / Trial / NCT03601806
Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection
Phase 2
Completed
26 enrolled
AIDS Malignancy Consortium
Montefiore Medical Center · collabNational Cancer Institute (NCI) · collabThe Emmes Company, LLC · collabUniversity of Arkansas · collabUniversity of California, Los Angeles · collabUniversity of Stellenbosch · collabWeill Medical College of Cornell University · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II clinical trial studies the side effects of pomalidomide and how well it works in treating patients with Kaposi sarcoma and human immunodeficiency virus (HIV) infection. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop tumor cells from growing and it may also block the growth of new blood vessels necessary for tumor growth.
Timeline
- Start
- 2021-04-26
- Primary completion
- 2024-11-29
- Completion
- 2025-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pomalidomide | Other / unclassified | — | Oral |